Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab by Coates, L, Rahman, P, Psaradellis, E, Rampakakis, E, Osborne, B, Lehman, A, Nantel, F

Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS by Gossec, L, Baraliakos, X, Aletaha, D, Sharaf, M, Rampakakis, E, Lavie, F, López-Medina, C, Selmi, C, Coates, LC

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase... by Coates, LC, Rahman, P, Mease, PJ, Shawi, M, Rampakakis, E, Kollmeier, AP, Xu, XL, Chakravarty, SD, McInnes, IB, Tam, L-S

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study by Coates, LC, Gossec, L, Zimmermann, M, Shawi, M, Rampakakis, E, Shiff, NJ, Kollmeier, AP, Xu, XL, Nash, P, Mease, PJ, Helliwell, PS